Representative End User Clients
Representative Automation Clients
Representative Software Clients
Dassault Systèmes has signed a definitive agreement to acquire ArisGlobal, an AI-native enterprise software provider serving the life sciences industry. The transaction is valued at approximately $1.8 billion in cash at closing, with up to $200 million in additional consideration linked to multiyear AI-related revenue milestones.
The acquisition is intended to expand Dassault Systèmes’ capabilities across regulatory affairs, pharmacovigilance, quality management, medical affairs, and real-world evidence. By combining these capabilities with its existing technologies for research and development, clinical trials, modeling and simulation, manufacturing, and quality, Dassault Systèmes aims to create a connected data and intelligence environment spanning the therapy lifecycle.
ArisGlobal serves more than 200 customers, including biopharmaceutical and biotechnology companies, medical device manufacturers, contract research organizations, and health authorities. Its platform processes more than 12 million patient safety cases annually, giving it a substantial role in regulated drug safety and compliance operations.
Extending Dassault Systèmes’ Life Sciences Portfolio
ArisGlobal provides software used to manage patient safety events, regulatory submissions, quality processes, and medical affairs activities. These processes are typically distributed across specialized systems and organizational functions, making it difficult for life sciences companies to maintain consistent data, traceability, and context throughout the product lifecycle.
The acquisition would connect these regulated operational processes with Dassault Systèmes’ existing life sciences portfolio, which includes BIOVIA for scientific research, Medidata for clinical development, and the 3DEXPERIENCE platform for virtual twins, modeling, simulation, manufacturing, and collaboration.
Dassault Systèmes expects this combination to establish a continuous evidence loop linking molecular research, clinical development, manufacturing, regulatory activities, postmarket safety data, and real-world patient outcomes. Information generated during one stage of the therapy lifecycle could therefore be made available to support decisions elsewhere in the organization.
Potential applications include using postmarket safety information to inform product development, connecting regulatory commitments with quality and manufacturing processes, and combining clinical and real-world evidence to improve the understanding of therapy performance.
AI for Regulated Life Sciences Processes
ArisGlobal’s NavaX platform applies AI to safety, regulatory, quality, and medical affairs workflows. The platform is designed to automate document-intensive activities, improve data quality, and generate intelligence within validated and highly regulated environments.
The combined portfolio is expected to support several areas:
Patient Safety and Pharmacovigilance: Managing adverse-event cases, safety signals, reporting obligations, and postmarket surveillance information.
Regulatory Operations: Coordinating submissions, product registrations, commitments, correspondence, and regulatory documentation across markets.
Quality Management: Connecting quality processes and records with product, manufacturing, safety, and regulatory information.
Medical Affairs: Managing medical information, scientific communications, and interactions with healthcare professionals and other stakeholders.
Clinical and Real-World Evidence: Bringing together clinical trial data and postmarket evidence to support safety, efficacy, and product lifecycle decisions.
AI-enabled Workflow Automation: Applying AI to classification, data extraction, document preparation, case processing, and other high-volume regulated activities.
The use of AI in these areas requires more than general-purpose language models. Systems must operate within controlled processes that support data lineage, validation, explainability, security, auditability, and human review. Combining ArisGlobal’s regulated workflow capabilities with Dassault Systèmes’ scientific modeling and virtual twin technologies could support the development of AI applications grounded in both operational evidence and scientific context.
Creating a Continuous Evidence Loop
Life sciences organizations often manage discovery, clinical development, manufacturing, quality, regulatory, and pharmacovigilance activities through separate systems. This fragmentation can limit the ability to trace how information and decisions move across the therapy lifecycle.
A unified platform could help organizations connect early research hypotheses with clinical outcomes, manufacturing performance, regulatory decisions, and postmarket patient evidence. This would allow teams to evaluate products using information collected before and after commercialization rather than treating each lifecycle stage as a separate process.
The acquisition also supports Dassault Systèmes’ broader strategy to combine virtual twins with AI and real-world data. Virtual models of molecules, therapies, manufacturing processes, and patient populations could be continuously refined using clinical and postmarket evidence, creating a feedback loop between simulation and observed outcomes.
Such an approach could help life sciences companies identify safety issues earlier, improve regulatory responsiveness, optimize clinical and manufacturing decisions, and reduce the time required to bring therapies through development. Its effectiveness, however, will depend on consistent data models, interoperability, governance, and the ability to preserve regulatory controls across the combined platform.
Transaction Details
ArisGlobal has more than 1,300 employees and is expected to generate approximately $175 million in revenue in 2026. Dassault Systèmes expects the acquisition to contribute to revenue growth and earnings per share during the first year following completion.
The transaction will be funded using cash from Dassault Systèmes’ balance sheet. It is expected to close during the second half of 2026, subject to regulatory approvals and customary closing conditions.
Related ARC Insights
The planned acquisition reflects the growing convergence of scientific modeling, clinical data, real-world evidence, regulatory operations, and governed AI across the life sciences product lifecycle. Related ARC Advisory Group coverage includes:
Accelerating Innovation and Time-to-Market in Life Sciences through AI-Powered Validation
AI-Driven Virtual Modeling and Simulation Accelerates the Drug Discovery Process
Follow ARC Advisory Group for the latest trends in life sciences, Industrial AI, regulatory compliance, virtual twins, and digital transformation.